Page 121 - Read Online

Nociti. Neuroimmunol Neuroinflammation 2020;7:291-9 I http://dx.doi.org/10.20517/2347-8659.2020.25 Page 299

51. Barker PA. Whither proBDNF? Nat Neurosci 2009;12:105-6.
52. Lu B, Pang PT, Woo NH. The yin and yang of neurotrophin action. Nat Rev Neurosci 2005;6:603-14.
53. Minichiello L. TrkB signalling pathways in LTP and learning. Nat Rev Neurosci 2009;10:850-60.
54. Lima Giacobbo B, Doorduin J, Klein HC, Dierckx RAJO, Bromberg E, et al. Brain-derived neurotrophic factor in brain disorders: focus
on neuroinflammation. Mol Neurobiol 2019;56:3295-312.
55. Marini AM, Jiang X, Wu X, Tian F, Zhu D, et al. Role of brain-derived neurotrophic factor and NF-kappaB in neuronal plasticity and
survival: From genes to phenotype. Restor Neurol Neurosci 2004;22:121-30.
56. Lai SW, Chen JH, Lin HY, Liu YS, Tsai CF, et al. Regulatory effects of neuroinflammatory responses through brain-derived neurotrophic
factor signaling in microglial cells. Mol Neurobiol 2018;55:7487-99.
57. Rossetti AC, Paladini MS, Trepci A, Mallien A, Riva MA, et al. Differential neuroinflammatory response in male and female mice: a role
for BDNF. Front Mol Neurosci 2019;12:166.
58. Egan MF, Kojima M, Callicott JH, Goldberg TE, Kolachana BS, et al. The BDNF val66met polymorphism affects activity-dependent
secretion of BDNF and human memory and hippocampal function. Cell 2003;112:257-69.
59. Shen T, You Y, Joseph C, Mirzaei M, Klistorner A, et al. BDNF polymorphism: a review of its diagnostic and clinical relevance in
neurodegenerative disorders. Aging Dis 2018;9:523-36.
60. D’Addario C, Dell’Osso B, Galimberti D, Palazzo MC, Benatti B, et al. Epigenetic modulation of BDNF gene in patients with major
depressive disorder. Biol Psychiatry 2013;73:e6-7.
61. Rao JS, Keleshian VL, Klein S, Rapoport SI. Epigenetic modifications in frontal cortex from Alzheimer’s disease and bipolar disorder
patients. Transl Psychiatry 2012;2:e132.
62. Mill J, Tang T, Kaminsky Z, Khare T, Yazdanpanah S, et al. Epigenomic profiling reveals DNA-methylation changes associated with
major psychosis. Am J Hum Genet 2008;82:696-711.
63. Ursini G, Cavalleri T, Fazio L, Angrisano T, Iacovelli L, et al. BDNF rs6265 methylation and genotype interact on risk for schizophrenia.
Epigenetics 2016;11:11-23.
64. Nociti V, Santoro M, Quaranta D, Losavio FA, De Fino C, et al. BDNF rs6265 polymorphism methylation in Multiple Sclerosis: a
possible marker of disease progression. PLoS One 2018;13:e0206140.
65. von Bartheld CS, Byers MR, Williams R, Bothwell M. Anterograde transport of neurotrophins and axodendritic transfer in the developing
visual system. Nature 1996;379:830-3.
66. Tonra JR, Curtis R, Wong V, Cliffer KD, Park JS, et al. Axotomy upregulates the anterograde transport and expression of brain-derived
neurotrophic factor by sensory neurons. J Neurosci 1998;18:4374-83.
67. Trapp BD, Peterson J, Ransohoff RM, Rudick R, Mörk S, et al. Axonal transection in the lesions of multiple sclerosis. N Engl J Med
1998;338:278-85.
68. Steinman L. Multiple sclerosis: a two-stage disease. Nat Immunol 2001;2:762-4.
69. Noseworthy JH, Lucchinetti C, Rodriguez M, Weinshenker BG. Multiple sclerosis. N Engl J Med 2000;343:938-52.
70. Bjartmar C, Trapp BD. Axonal and neuronal degeneration in multiple sclerosis: mechanisms and functional consequences. Curr Opin
Neurol 2001;14:271-8.
71. Caggiula M, Batocchi AP, Frisullo G, Angelucci F, Patanella AK, et al. Neurotrophic factors and clinical recovery in relapsing-remitting
multiple sclerosis. Scand J Immunol 2005;62:176-82.
72. Sarchielli P, Greco L, Stipa A, Floridi A, Gallai V. Brain-derived neurotrophic factor in patients with multiple sclerosis. J Neuroimmunol
2002;132:180-8.
73. Azoulay D, Urshansky N, Karni A. Low and dysregulated BDNF secretion from immune cells of MS patients is related to reduced
neuroprotection. J Neuroimmunol 2008;195:186-93.
74. Azoulay D, Vachapova V, Shihman B, Miler A, Karni A. Lower brain-derived neurotrophic factor in serum of relapsing remitting MS:
reversal by glatiramer acetate. J Neuroimmunol 2005;167:215-8.
75. Hamamcioglu K, Reder AT. Interferon-beta regulates cytokines and BDNF: greater effect in relapsing than in progressive multiple
sclerosis. Mult Scler 2007;13:459-70.
76. Ineichen BV, Plattner PS, Good N, Martin R, Linnebank M, et al. Nogo-A antibodies for progressive multiple sclerosis. CNS Drugs
2017;31:187-98.
77. Ruggieri S, Tortorella C, Gasperini C. Anti lingo 1 (opicinumab) a new monoclonal antibody tested in relapsing remitting multiple
sclerosis. Expert Rev Neurother 2017;17:1081-9.
78. Crozier RA, Bi C, Han YR, Plummer MR. BDNF modulation of NMDA receptors is activity dependent. J Neurophysiol 2008;100:3264-
74.
79. Obermeyer JM, Tuladhar A, Payne SL, Ho E, Morshead CM, et al. Local delivery of brain-derived neurotrophic factor enables behavioral
recovery and tissue repair in stroke-injured rats. Tissue Eng Part A 2019;25:1175-87.
80. Huang Y, Dreyfus CF. The role of growth factors as a therapeutic approach to demyelinating disease. Exp Neurol 2016;283:531-40.
81. Kopec BM, Kiptoo P, Zhao L, Rosa-Molinar E, Siahaan TJ. Noninvasive brain delivery and efficacy of bdnf to stimulate
neuroregeneration and suppression of disease relapse in EAE mice. Mol Pharm 2020;17:404-16.